Gilead Sciences — 2022 Investments

1 investments dated 2022 · listed companies and verified rows first · show all

Curebasecurebase.ai in 𝕏Series B · May 2022 · $40M

Curebase offers an AI-powered eClinical software platform for running clinical trials, with tools including ePRO, eConsent, participant engagement, and integrated EDC.

AI & Machine LearningBiotechDigital HealthHealthtechSaaSFort Lauderdale, US

Storm Stillman(COO)inTom Lemberg(Founder)inMatthew Rials(CTO)Noah Debrincat(Lead Product Manager)inHannah Gittleman(Head of People)Sam Oliver(Lead Recruiter)

Co-investorsAcrew Capital Bold Capital Partners Breyer Capital C3 Ventures Future Planet Capital Gaingels +15 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.